AI-generated analysis. Always verify with the original filing.
Cabaletta Bio, Inc. announced financial results for the fourth quarter and full year ended December 31, 2025, with research and development expenses of $36.2 million and $142.7 million, respectively, and cash, cash equivalents and short-term investments of $133.6 million as of December 31, 2025. The company provided business updates on rese-cel clinical programs, including myositis registrational cohort enrollment and upcoming data presentations in 1H26.
Event Type
Disclosure
Mandatory
Variant
8-K
Results of Operations and Financial Condition. On March 23, 2026, Cabaletta Bio, Inc. (the "Company") announced its financial results for the fourth quarter and
of this Current Report on Form 8-K. The information contained in Item 2.02 and Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 at
Financial Statements and Exhibits. (d) Exhibits 99.1 Press Release issued by the registrant on March 23, 2026, furnished herewith. 99.2 Cabaletta Bio, Inc. Corp
| Metric | Value | Basis |
|---|---|---|
| Research and development expenses | $36.20 | |
| Research and development expenses | $142.70 | |
| General and administrative expenses | $6.40 | |
| General and administrative expenses | $29.60 |